Shares of ClearOne Inc. (CLRO) tumbled 8.8% to $3.43 on October 13 after Nasdaq notified the company it no longer meets the exchange's minimum $2.5 million stockholders' equity requirement — a threshold that, if not remedied, will result in its stock being removed from the exchange entirely. ClearOne Gets the Nasdaq Boot for Vanishing Equity — Can a Last-Ditch Merger Save It From the Abyss?
Shares of ClearOne (CLRO) sank 8.8% to $3.43 after Nasdaq formally moved to delist the company for failing to maintain the exchange's $2.5 million minimum stockholders' equity — essentially, the company's net worth has fallen below the floor Nasdaq demands for any listed stock.
• A Six-Month Cure Period Expired With Nothing to Show for It. Nasdaq first warned ClearOne in April 2026 that it was out of compliance.
The exchange granted a 180-day exception — through October 5 — for the company to fix the problem.
On October 8, Nasdaq ruled ClearOne had not completed the remedial actions in its May compliance plan and determined to delist the company's securities. The appeal hearing, which ClearOne intends to request by October 15, would automatically pause any delisting action — but the clock is ticking.
• The Company Is Essentially a Shell With Barely Any Equity Left. ClearOne sold substantially all its operating assets and intellectual property to Biamp Systems in October 2025 and generated no revenue from continuing operations in Q1 2026.
As of its most recent filing, total shareholder equity was just $532,000 against $2.0 million in total assets and $1.5 million in liabilities. That's a fraction of the $2.5 million Nasdaq requires.
• A Reverse Merger Is Supposed to Be the Escape Hatch — But Delisting Threatens It. ClearOne struck a deal to merge with Cortigent, a brain-implant device maker spun from Vivani Medical, with pricing and closing expected in October 2026.
The deal includes raising $10–$15 million in new capital at closing. But here's the catch: the merger agreement requires ClearOne's stock to remain listed on Nasdaq through the closing date. If the appeal fails, the deal unravels. Post-merger, existing ClearOne shareholders would own just 12.7%–14.4% of the combined entity — a steep dilution even in the best case.
• Shareholders Face a Lose-Lose Scenario in the Near Term. Delisting would significantly reduce liquidity and likely crater the stock price further , while banishment to the over-the-counter markets would make it far harder to sell shares at a desired price. With a market capitalization under $10 million, cash of just $1.05 million as of March , and continuing losses, ClearOne's survival as a listed company hinges entirely on whether the appeal buys enough time for the Cortigent merger to close. That's a thin thread for any investor to hang onto.